Neural Operant Conditioning

October 27, 2023 updated by: James Sulzer, MetroHealth Medical Center

Neural Operant Conditioning to Improve Walking After Stroke

The goal of this clinical trial is to learn if operant conditioning can reduce spasticity in order to improve walking in stroke patient. The main questions it aims to answer are:

  • Can participants self-regulate reflex excitability
  • Can participants self-regulate reflex, reduce spasticity and improve walking Participants will undergo surface stimulation to evoke spinal reflexes and will be asked to control these reflexes therefore reducing spasticity.

Researchers will compare result to able bodied participants to see if [insert effects]

Study Overview

Detailed Description

The study purpose is to investigate the possibility and later effect of spinal reflex self-regulation in post-stroke stiff-knee gait. The intervention will consist of direct current surface stimulation of the peripheral nerves using electrical stimulation. Stimulation will evoke a motor response that will be collected through surface EMG electrodes and processed to depict a measure of the response as feedback to the participant to complete the loop of operant conditioning. The participant will attempt to modulate their responses over multiple sessions to cause this depiction to either increase or decrease its value depending on an established target.

.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Ohio
      • Cleveland, Ohio, United States, 44109
        • Recruiting
        • MetroHealth Medical Center
        • Contact:
        • Principal Investigator:
          • James Sulzer, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Sign and date consent form
  2. At least 3 months since stroke event
  3. Over 18 years of age at time of eligibility
  4. Ability to stand upright and walk for at least 5 minutes
  5. Premorbidly independent
  6. Mild to moderate gait impairment
  7. Reduced knee flexion during walking relative to the unimpaired side
  8. Unilateral hemiparesis of the lower limbs
  9. Ability to evoke muscle responses through peripheral nerve stimulation, spinal cord stimulation, and transcranial magnetic stimulation
  10. Medically stable
  11. Skin intact on hemiparetic leg, abdomen, and scalp
  12. Ability to evoke muscle responses and/or reflex responses through peripheral nerve stimulation, spinal cord stimulation, and/or transcranial magnetic stimulation

Exclusion Criteria:

  1. Co-existing neurological condition other than prior stroke involving the hemiparetic lower limb (e.g., peripheral nerve injury, PD, SCI, TBI, MS).
  2. History of lower limb musculoskeletal injury
  3. Functionally relevant osteoarthritis and weight bearing restriction
  4. Functionally relevant polyneuropathy resulting in lack of sensation in the lower leg
  5. Functionally relevant cognitive impairment
  6. Functionally relevant vision impairment
  7. Pregnant
  8. Botox injection to the ipsilateral leg in the last 12 weeks or taking oral anti-spasticity medications
  9. Taking part in physical therapy for any walking-related impairment
  10. Cardiac pacemaker or other implanted electronic systems
  11. Uncontrolled seizure disorder
  12. Use of seizure lowering threshold medications and the discretion of the study physician
  13. Deficits in communication that interfere with reasonable study participation
  14. Severely impaired cognition and communication
  15. Severe lower limb pain

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental: Post-stroke Stiff-Knee Gait Participants
Individuals with post-stroke Stiff-Knee gait
Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Surface electromyographic recording of leg muscles
Time Frame: baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment
Recording electrical activity of leg muscles during walking in response to peripheral nerve stimulation
baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
10 meter walk test
Time Frame: baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment
10 meter walk test with collection of gait kinematics captured using an inertial motion capture camera system
baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment
quadriceps pendulum test
Time Frame: baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment
This is a method of evaluating spasticity using gravity to provoke the muscular stretch reflex allowing for the collection of joint angle data. This data will aid in assessing changes in joint angles as a result of training.
baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment
Five Times Sit to Stand Test
Time Frame: baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment
measures lower extremity functional strength. This test will measure your leg strength by asking you to sit down and stand up from a chair 5 times as fast as possible.
baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment
TMS
Time Frame: Baseline, Week 12 - end of treatment
non-invasive brain stimulation device, will be used to elicit a motor evoked response in participants via low frequency stimulation to the cortical regions associated with the muscles being investigated. This approach will test the integrity of the participant's CST in relation to the intervention and assessments being conducted
Baseline, Week 12 - end of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: James Sulzer, PhD, MetroHealth Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 31, 2024

Primary Completion (Estimated)

May 31, 2027

Study Completion (Estimated)

May 31, 2028

Study Registration Dates

First Submitted

October 23, 2023

First Submitted That Met QC Criteria

October 27, 2023

First Posted (Actual)

November 2, 2023

Study Record Updates

Last Update Posted (Actual)

November 2, 2023

Last Update Submitted That Met QC Criteria

October 27, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Peripheral Nerve Stimulation

3
Subscribe